Profile data is unavailable for this security.
About the company
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. It develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. It is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.
- Revenue in USD (TTM)0.00
- Net income in USD-20.07m
- Incorporated2015
- Employees7.00
- LocationBluejay Diagnostics Inc360 Massachusetts Avenue, Suite 203ACTON 01720United StatesUSA
- Phone+1 (978) 631-0152
- Fax+1 (302) 636-5454
- Websitehttps://bluejaydx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clearmind Medicine Inc | 0.00 | -3.86m | 1.74m | -- | -- | 0.1538 | -- | -- | -30.64 | -30.64 | 0.00 | 7.54 | 0.00 | -- | -- | -- | -57.83 | -128.70 | -178.71 | -360.04 | -- | -- | -- | -- | -- | -- | 0.5987 | -- | -- | -- | 26.60 | -- | -- | -- |
| Exousia Pro Inc | 0.00 | -854.02k | 1.84m | 0.00 | -- | -- | -- | -- | -0.0642 | -0.0642 | 0.00 | -0.0318 | 0.00 | -- | -- | -- | -1,313,877.00 | -- | -- | -- | -- | -- | -- | -- | -- | -1,816.06 | -- | -- | -- | -- | -248.31 | -- | -- | -- |
| Zyversa Therapeutics Inc | 0.00 | -25.70m | 1.94m | 7.00 | -- | -- | -- | -- | -4.46 | -4.46 | 0.00 | -1.45 | 0.00 | -- | -- | 0.00 | -251.13 | -- | -- | -- | -- | -- | -- | -- | -- | -14.60 | -- | -- | -- | -- | 91.14 | -- | -- | -- |
| Yubo International Biotech Ltd | -20.00 | -1.23m | 1.96m | 18.00 | -- | -- | -- | -- | -0.0099 | -0.0099 | 0.00 | -0.0098 | -0.00002 | -0.0005 | -- | -1.11 | -105.87 | -- | -- | -- | -- | -- | -- | -- | 0.2394 | -- | -- | -- | -99.43 | -- | -48.55 | -- | -- | -- |
| CDT Equity Inc | 0.00 | -20.70m | 2.03m | 6.00 | -- | 0.3282 | -- | -- | -473.79 | -473.79 | 0.00 | 3.35 | 0.00 | -- | -- | 0.00 | -358.56 | -- | -- | -- | -- | -- | -- | -- | -- | -16.00 | 0.2881 | -- | -- | -- | -3,227.48 | -- | -- | -- |
| VG Life Sciences Inc | 0.00 | -4.30m | 2.11m | 7.00 | -- | -- | -- | -- | -0.0721 | -0.0721 | 0.00 | -0.0491 | 0.00 | -- | -- | -- | -384.41 | -294.08 | -- | -- | -- | -- | -- | -587,591.90 | -- | -1.70 | -- | -- | -- | -- | 16.58 | -- | -- | -- |
| Bluejay Diagnostics Inc | 0.00 | -20.07m | 2.11m | 7.00 | -- | 0.3307 | -- | -- | -134.42 | -134.42 | 0.00 | 9.01 | 0.00 | -- | -- | 0.00 | -103.46 | -70.71 | -124.04 | -82.92 | -- | -- | -- | -12,694.84 | -- | -- | 0.0028 | -- | -- | -- | -110.38 | -- | 119.51 | -- |
| Azitra Inc | 0.00 | -11.12m | 2.20m | 12.00 | -- | 0.5041 | -- | -- | -5.49 | -5.49 | 0.00 | 0.4066 | 0.00 | -- | -- | 0.00 | -157.91 | -- | -203.88 | -- | -- | -- | -- | -- | -- | -- | 0.1197 | -- | -98.91 | -- | 29.05 | -- | -- | -- |
| CNS Pharmaceuticals Inc | 0.00 | -13.07m | 2.25m | 4.00 | -- | 0.2105 | -- | -- | -130.83 | -130.83 | 0.00 | 17.25 | 0.00 | -- | -- | 0.00 | -135.60 | -153.00 | -197.11 | -237.57 | -- | -- | -- | -- | -- | -- | 0.0031 | -- | -- | -- | 21.18 | -- | -26.93 | -- |
| Mosaic Immunoengineering Inc | 0.00 | -671.75k | 2.27m | 2.00 | -- | -- | -- | -- | -0.0928 | -0.0928 | 0.00 | -1.01 | 0.00 | -- | -- | 0.00 | -1,410.50 | -- | -- | -- | -- | -- | -- | -- | -- | -7.37 | -- | -- | -- | -- | 8.56 | -- | -- | -- |
| Purminds Enterprises Inc | 0.00 | -77.46k | 2.32m | 0.00 | -- | 0.0641 | -- | -- | -0.1832 | -0.1832 | 0.00 | 0.7646 | 0.00 | -- | -- | -- | -26.19 | -620.48 | -66.38 | -- | -- | -- | -- | -- | -- | -6.29 | 0.00 | -- | -- | -- | -13.29 | -- | -- | -- |
| Bone Biologics Corp | 0.00 | -3.95m | 2.33m | 2.00 | -- | 0.3879 | -- | -- | -7.30 | -7.30 | 0.00 | 3.35 | 0.00 | -- | -- | 0.00 | -75.76 | -86.22 | -80.46 | -561.06 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.15 | -- | -- | -- |
| Revelation Biosciences Inc | 0.00 | -14.08m | 2.38m | 8.00 | -- | 0.1222 | -- | -- | -120.02 | -120.02 | 0.00 | 12.27 | 0.00 | -- | -- | 0.00 | -82.96 | -- | -118.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12,406.06 | -- | -- | -- |
| AIM ImmunoTech Inc | 112.00k | -15.75m | 2.41m | 21.00 | -- | -- | -- | 21.51 | -19.82 | -19.82 | 0.1067 | -2.20 | 0.0117 | -- | -- | 5,333.33 | -165.08 | -50.43 | -637.78 | -55.23 | 15.18 | -113.19 | -14,062.50 | -12,238.47 | -- | -- | -- | -- | -15.84 | 3.96 | 40.20 | -- | -45.22 | -- |
| Cardio Diagnostics Holdings Inc | 15.79k | -6.55m | 2.41m | 13.00 | -- | 0.2861 | -- | 152.65 | -4.07 | -4.07 | 0.0097 | 4.61 | 0.0024 | -- | 1.25 | 1,214.62 | -98.75 | -- | -104.31 | -- | -- | -- | -41,495.31 | -- | -- | -440.22 | 0.00 | -- | 104.39 | -- | -0.079 | -- | -- | -- |
| Lyra Therapeutics Inc | 600.00k | -32.95m | 2.43m | 30.00 | -- | -- | -- | 4.05 | -23.78 | -23.78 | 0.418 | -2.63 | 0.0098 | -- | -- | 20,000.00 | -53.81 | -64.59 | -67.22 | -76.36 | -- | -- | -5,491.17 | -5,844.58 | -- | -- | -- | -- | -1.54 | -- | -49.07 | -- | 61.78 | -- |
Data as of Feb 12 2026. Currency figures normalised to Bluejay Diagnostics Inc's reporting currency: US Dollar USD
5.17%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| DRW Securities LLCas of 30 Sep 2025 | 59.77k | 3.30% |
| Sabby Management LLCas of 30 Sep 2025 | 29.63k | 1.63% |
| Tower Research Capital LLCas of 30 Sep 2025 | 4.45k | 0.25% |
| Bank of America, NA (Private Banking)as of 30 Sep 2025 | 12.00 | 0.00% |
| L1 Capital Global, Inc.as of 31 Dec 2024 | 0.00 | 0.00% |
| Citigroup Global Markets, Inc. (Investment Management)as of 30 Sep 2025 | 0.00 | 0.00% |
More ▼
Data from 30 Sep 2025 - 15 Jan 2026Source: FactSet Research Systems Inc.
